about us

press release

contact

Home

Executives

Acquisitions/Mergers

Funding

FDA Updates

Clinical Trials

Medical Device News

HomePharmaEagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch...

Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Par Pharmaceutical, Inc. (“Par”) has unilaterally withdrawn its request that the U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product. Par’s appeal of the District Court’s ruling on August 31, 2021, that Eagle’s vasopressin product does not infringe any of the patents asserted by Par against Eagle remains pending, and Eagle will continue to vigorously defend against such appeal.

“We look forward to advancing our launch plans for this important product, and we believe this withdrawal re-affirms our confidence in ultimate success,” stated Scott Tarriff, President and Chief Executive Officer of Eagle.